🎉 Health Canada Provides a No Objection Letter for ATMA’s N500 Phase II Clinical Trial Application

Psilocybin-assisted therapy is becoming an increasingly widespread treatment for various mental health conditions. However, many healthcare professionals may be hesitant to use this type of treatment with their patients because of the misconception that psychedelics are dangerous and unsafe. This blog post will share evidence of the safety of psilocybin as an effective treatment option when facilitated by a trained healthcare practitioner.

 

Psychedelics have been used for centuries by various cultures for healing purposes. In recent years, there has been a resurgence of interest in the therapeutic potential of psychedelics. Psilocybin-assisted therapy is a promising treatment for anxiety, depression, PTSD, and end-of-life distress.

With the right set and setting, psilocybin is generally very safe. In fact, it is often safer and more efficacious than many other medications currently prescribed for mental health conditions.

Click to read full abstract

Additionally, in a study published in the Journal of Psychopharmacology titled  Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms, [in o]ut of 9233 past year magic mushroom users, [only] 19 (0.2%) reported having sought emergency medical treatment.” As further explained, “Young age was the only predictor associated with higher risk of emergency medical presentations. The most common symptoms were psychological, namely anxiety/panic and paranoia/suspiciousness. Poor ‘mindset’, poor ‘setting’ and mixing substances were most reported reasons for incidents. All but one respondent returned back to normality within 24 h.”

If patients are screened by their physician prior to consumption, and if they are accompanied by a trained facilitator during the session, many of the risks would be eliminated that could result in the need for emergency medical treatment. As healthcare professionals, it is important to understand the facts regarding psilocybin, and be able to differentiate these facts from stigma as this field continues to grow. 

Research is regularly being published in medical journals speaking to the safety of psilocybin… but is it more efficacious than conventional treatments at treating mental health concerns?

Given that psilocybin has been granted breakthrough treatment by the FDA twice in the last three years, legal psilocybin treatment could be available sooner than later. The results of studies continue to show the potential that psilocybin-assisted therapy has to offer. 

As explained by researchers at Johns Hopkins Medicine who studied major depressive disorder, “two doses of the psychedelic substance psilocybin, given with supportive psychotherapy, produced rapid and large reductions in depressive symptoms, with most participants showing improvement and half of study participants achieving remission through the four-week follow-up.”

Most mental health conditions are treated with psychotropic medications that must be taken daily; if the desired effect is not produced, the dosage is increased, which simultaneously increases the risk of potential side effects. Psilocybin, on the other hand, requires only a few treatments per year to produce the same effects or better.

So which medicine would you choose for your patients?

Learning the basics about psychedelics is valuable in order to support your patients in the best way possible.  Book a call to see if ATMA’s Introduction to Psychedelic-assisted Therapy program is right for you. 

Thank you,

The ATMA Academy Team

More News and Media:

Health Canada Provides a No Objection Letter for ATMA’s N500 Phase II Clinical Trial Application, Paving the Way for the Largest Psilocybin Trial to Date

This trial will assess psilocybin efficacy in frontline healthcare professionals suffering from COVID-19-related mental wellness challenges. CALGARY, AB, Sept. 14, 2022 /CNW/ – ATMA Journey Centers Inc. (“ATMA”), an Alberta-based company focused on the international delivery of innovative psychedelic-assisted therapy solutions, announced today that it has received approval from Health Canada to move forward with its N500 Phase II psilocybin

Psychedelic Breakthrough

Breakthroughs in the Therapy Room – Hope for Treatment Resistant Mental Illness?

By Rachel Dundas, Registered Psychologist Certified Trauma Practitioner   The Role of Psychedelics in Therapeutic Breakthroughs One of the main goals of psychotherapy is to guide patients toward therapeuticbreakthroughs – defined as a significant, sometimes sudden, step forward or important realization. Oftentimes, in therapy, breakthroughs come after long, unproductive plateaus. Such realizations must come from

ATMA Journey Centers observes positive outcomes from a Phase I clinical trial of psilocybin in healthy participants

Fourteen healthy subjects completed an experiential session after receiving 25 mg psilocybin  – Results of this phase I study will inform the design of Phase II study in frontline healthcare workers, examining the efficacy of psilocybin for Covid-related stress. Calgary, September 7, 2022 — ATMA Journey Centers (the “Company”), a company providing therapist training and support, has

Thank You Letter

Dear mental healthcare professionals, A deep heart-felt thank you is warranted to you for bearing the weight of the current mental health crisis, especially during these last tough couple of years. I have heard from many of your peers regarding the increased pressure, overburdening workloads, and feelings of burnout that have become an all too frequent occurrence.

Breaking Through the Stigma

By David Harder, ATMA co-founder and co-CEO I met with a gentleman – a pastor of sorts – from my former religious life. We sat down to enjoy a pint and a burger at a local watering hole. It had been many years since we had last spoken, simply due to the chaos of life,

How To Change Your Mind

Upon the release of his book How to Change Your Mind, Michael Pollan sparked a major shift in the mindset of numerous therapists and medical professionals, as well as the general public. At the time of its publication in the spring of 2019, discussions surrounding psychedelics were happening, but in small, hushed groups of underground

Clinical Trials and Psychedelics

Clinical trials are the standard way to evaluate the safety and efficacy of new drugs (including psychedelic drugs) for medical use. Clinical trials also serve to test novel treatment options, explore ways to improve quality of life for people living with illnesses or diseases, and assess whether a new drug or treatment has fewer side

Magic Mushroom - ATMA

Magic Mushrooms (Psilocybin) and End-of-life

End-of-life distress has been an ongoing focus for psilocybin clinical trials, as psilocybin has the potential to offer relief for existential distress when other forms of treatment fail. Health Canada has granted access to psilocybin through the Section 56 Exemption program, which is a patient led application requesting access to psilocybin. These exemptions are reviewed

Scroll to Top